Home » Archive by Category


R & D Lab Technician – Wondfo USA Company, Ltd. – San Diego, CA

October 13, 2014 – 8:54 am | Edit Post

WONDFO Biotech China quickly grew beyond research and development into a manufacturer of quality medical products and biochemical reagents….
From CareerBuilder – 13 Oct 2014 15:54:00 GMT
– View all San Diego jobs

R & D Lab Scientist – Wondfo USA Company, Ltd. – San Diego, CA

October 13, 2014 – 8:48 am | Edit Post

WONDFO Biotech China quickly grew beyond research and development into a manufacturer of quality medical products and biochemical reagents….
From CareerBuilder – 13 Oct 2014 15:48:57 GMT
– View all San Diego jobs

Reflections on Advances in Medicinal Oligonucleotides

October 13, 2014 – 8:29 am | Edit Post

Oligos Are Not “Magic Bullets” Oligos Have, Nevertheless, Enabled New Drug Paradigms Oligos Continue to Attract Significant Corporate Investments Reflections The 10th Annual Meeting of the Oligonucelotide Therapeutics Society (OTS) is in full swing today in San Diego, CA where … Continue reading →
The post Reflections on Advances in Medicinal Oligonucleotides appeared first on Zone in With Zon.

10-20 Science Tutors Needed: Bio, Physics, Chem, Orgo, Anatomy (San Diego Metro and All Suburbs)

October 13, 2014 – 8:26 am | Edit Post

Varsity Tutors is a national leader in the tutoring industry. We are seeking exceptional tutors to join our growing team! Apply here: http://www.varsitytutors.com/san_diego-tutoring-jobs
To apply, please complete the online application at http://www [...]

Director, Translational Oncology – Pfizer Inc – La Jolla, CA

October 13, 2014 – 7:37 am | Edit Post

Pfizers Biotechnology Clinical Development group is seeking an experienced scientist or physician scientist to lead its Translational Oncology efforts….
From Pfizer Inc – 17 Oct 2014 09:04:47 GMT
– View all La Jolla jobs

Philips and Radboud university medical center debut wearable diagnostic prototype for chronic illness at Dreamforce 2014 event

October 13, 2014 – 7:00 am | Edit Post

ANDOVER, Mass. and SAN FRANCISCO, Oct. 13, 2014 /PRNewswire/ – Today at the Dreamforce 2014 conference in San Francisco, Royal Philips (NYSE: PHG; AEX: PHIA) and Nijmegen NL-based Radboud university medical center (Radboudumc) announced the debut of a prototype to support patients with chronic obstructive pulmonary disease (COPD). The launch marks the start of joint explorations between Philips and Radboudumc to apply mobile, digital and cloud technologies to improve patient outcomes, care coordination and patient empowerment across the health continuum.

According to the US Centers for Disease Control and Prevention (CDC), 117 million Americans, or nearly one-half of the US adult population, have at least one chronic condition, and one in four adults has two or more.  The CDC estimates that caring for patients with chronic conditions accounts for 70% of the annual health care spend in the U.S.  In a study released by The World Economic Forum, the global economic impact of the five leading non-communicable diseases – cardiovascular disease, chronic respiratory disease, cancer, diabetes and mental ill-health – could total $47 trillion over the next 20 years.

Management of COPD is challenging and often costly, as the progressive nature of the disease leads many patients to require complicated therapies and frequent hospital readmissions. At the same time, consumers are increasingly looking for new ways to take control of their personal health in order to live healthier and better lives.

“Unlike other wearable solutions recently introduced to the market, this prototype collects more than just wellness data from otherwise healthy people,” said Jeroen Tas, CEO, Healthcare Informatics Solutions and Services, Philips. “We are demonstrating the power of harnessing both clinical and personal health information to better manage chronic disease patients across the health continuum, from healthy living, prevention, diagnosis, treatment, recovery and home care.”

How it works

The wearable diagnostic prototype for COPD patients feeds data collected from patients at home to clinicians through the Philips HealthSuite Digital Platform to two clinical applications currently available on the cloud-based platform – eCareCompanion and eCareCoordinator – which both recently received FDA 510(k) clearance. Once a COPD patient has left the hospital, a wearable diagnostic prototype collects data day and night – including physical activity/inactivity, respiratory indicator, heart rhythm and heart rate variability. That data is then sent via the cloud to the Philips HealthSuite Digital Platform, where it is shared with the appropriate care providers via the eCareCoordinator application, presenting a more complete view of the patient’s illness.

“Together with Philips, we are exploring and developing tools to enable patients to be true partners in their own health care, including Hereismydata™ and thus creating a digital platform for patients to collect data from EMRs as well as personal wearable technology,” said Lucien Engelen, director REshape Innovation Center at Radboud university medical center. “Our collaboration with Philips creates the scale needed for a globalizing sustainable healthcare approach.”

Radboudumc is considered to be one of the most innovative medical centers in Europe focused on digital solutions to enable patient centric care. The innovation center at Radboudumc, part of the network of Singularity University’s Exponential Medicine track in Silicon Valley, is at the forefront of the convergence of technology and patient empowerment, both inside and outside the hospital.  

As part of Philips vision for the HealthSuite Digital Platform, the company is working to create a suite of open application programming interfaces (APIs) that can be used by developers to create innovative applications for hospitals and health systems. Visitors to the Philips booth in the Salesforce Customer Showcase at Dreamforce can sign up to learn more about this Developers Toolkit, expected to be available in early 2015.

Members of the press and conference attendees can learn more about the Philips-Radboudumc  innovative COPD prototype at the Dreamforce 2014 conference in San Francisco from October 13-16: Demos will be shown at the Dreamforce Industry Health and Life Sciences Showcase (Moscone South/Gateway) and the Customer Showcase areas (Moscone West).

For updates on further platform developments, visit www.philips.com/dreamforce and follow the #DF14 conversation at @PhilipsHealth.

For further information, please contact:

Kathy O’ReillyPhilips(o) 978-659-2638 (mobile) 978-221-8919Kathy.oreilly@philips.comTwitter: @kathyoreilly

Sabine van DeursenPhilips+31 6 15043894Sabine.van.deursen@philips.comTwitter: @sabinevdeursen

Viola PeulenRadboudumc+31 24 3668799 (mobile) +31 6 55346484Viola.peulen@radboudumc.nl

Salesforce and others are trademarks of salesforce.com, inc.

About Royal Philips:Royal Philips (NYSE: PHG, AEX: PHIA) is a diversified health and well-being company, focused on improving people’s lives through meaningful innovation in the areas of Healthcare, Consumer Lifestyle and Lighting. Headquartered in the Netherlands, Philips posted 2013 sales of EUR 23.3 billion and employs approximately 112,000 employees with sales and services in more than 100 countries. The company is a leader in cardiac care, acute care and home healthcare, energy efficient lighting solutions and new lighting applications, as well as male shaving and grooming and oral healthcare. News from Philips is located at www.philips.com/newscenter.

About Radboud university medical centerRadboud university medical center is an institute for patient care, research and education & training, located in Nijmegen, the Netherlands. Our mission is to have a significant impact on healthcare. We aim to be a frontrunner in the development of innovative, sustainable and affordable healthcare. By offering excellent quality, participatory and personalized healthcare, operational excellence and sustainable networks. Our almost 10,000 employees and over 3,000 students do their utmost every day to make a positive contribution to the future of healthcare and medical sciences.



Related LinksPhilips Presence at DreamforcePhilips HealthSuite Digital Platform

Video – http://origin-qps.onstreammedia.com/origin/multivu_archive/PRNA/ENR/FX-MM35608-20141012-1.mp4Video – http://origin-qps.onstreammedia.com/origin/multivu_archive/PRNA/ENR/FX-MM35608-20141012-2.mp4Infographic – http://photos.prnewswire.com/prnh/20141012/151645-INFOLogo – http://photos.prnewswire.com/prnh/20140122/NE50581LOGO
SOURCE Royal Philips

Kythera Biopharmaceuticals Grants Stock Options Under Inducement Program

October 13, 2014 – 5:00 am | Edit Post

WESTLAKE VILLAGE, Calif., Oct. 10, 2014 (GLOBE NEWSWIRE) — KYTHERA Biopharmaceuticals, Inc. (Nasdaq:KYTH) today announced that on September 26, 2014, the Compensation Committee of the Company’s Board of Directors granted two new employees options to purchase an aggregate of 12,500 shares of the Company…

Spinal Atrophy Drug From Isis Pharmaceuticals, Inc. Showing Promise, Says UBS

October 13, 2014 – 5:00 am | Edit Post

Cytori Therapeutics, Inc. Announces Closing Of Financing

October 13, 2014 – 5:00 am | Edit Post

SAN DIEGO–(BUSINESS WIRE)–Cytori Therapeutics, Inc. (NASDAQ: CYTX) announced today that it has completed the previously announced sale of shares of its Series A 3.6% convertible preferred stock pursuant to a registered direct offering representing gross proceeds of approximately $13.5 million. The preferred stock is convertible into shares of Cytoris common stock at the option of the investors at…

Tobira Therapeutics Doses First Patient in CENTAUR, A Phase 2b Study of Cenicriviroc in Patients with Non-Alcoholic Steatohepatitis

October 13, 2014 – 5:00 am | Edit Post

SOUTH SAN FRANCISCO, Calif., Oct. 13, 2014 /PRNewswire/ – Tobira Therapeutics, Inc., a clinical-stage biopharmaceutical company advancing cenicriviroc (CVC) in liver disease and HIV, announced today that it has dosed the first patient in its CENTAUR study of patients with non-alcoholic steatohepatitis (NASH) and liver fibrosis, a disease affecting approximately 3-5 percent of the U.S. population. The initiation of the CENTAUR study follows the completion of a Phase 1 safety study in subjects with liver cirrhosis. To date, approximately 580 subjects have been dosed with CVC in Phase 1 and Phase 2b clinical studies, including 115 HIV-1 infected subjects on treatment for up to 48 weeks.

“Initiating a Phase 2b clinical study with CVC in NASH, a potentially life threatening liver disease for which there are no approved therapies, is an important milestone for Tobira,” commented Dr. Laurent Fischer, chairman and CEO of Tobira Therapeutics. “CVC has previously demonstrated dual inhibition of CCR2 and CCR5, key regulators of signaling pathways in NASH that lead to liver damage and disease. This study will help further determine if these drivers are responsive to CVC and advance our clinical investigation of a potential treatment option for patients with NASH.” 

CVC is an oral, once-daily, potent immunomodulator that blocks two chemokine receptors, CCR2 and CCR5, which are intricately involved in the inflammatory and fibrogenic pathways in NASH that cause liver damage and often lead to cirrhosis, liver cancer or liver failure. Tobira has demonstrated significant anti-fibrotic activity of CVC in preclinical models of liver and kidney disease.

“The rising prevalence of obesity in the United States and Western Europe is associated with an alarming increase in NASH leading to advanced liver fibrosis and cirrhosis. Cenicriviroc – with its favorable safety profile and scientific evidence of an anti-inflammatory and anti-fibrotic effect – is the first drug in its class in development to target the damage and scarring resulting from fat and inflammation in the liver,” stated Scott Friedman, M.D., chief of the Division of Liver Diseases and Dean of Therapeutic Discovery at the Icahn School of Medicine at Mount Sinai, and a world renowned NASH expert. Dr. Friedman is the CENTAUR study chairman.

The CENTAUR study is a randomized, double-blind Phase 2b study of a single 150mg tablet of CVC given once daily versus placebo in patients with NASH and liver fibrosis. CENTAUR is a global study with planned treatment centers across North America, Europe and Australia. The study will enroll approximately 250 patients and will evaluate the improvement of NASH and liver fibrosis at both one and two years as compared to placebo. For additional information on the CENTAUR study, please visit clinicaltrials.gov using the identifier NCT02217475.

About Tobira Therapeutics

Tobira is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapies to treat liver disease, HIV, fibrosis and inflammation. The company’s lead product, cenicriviroc (CVC), is a first in class immunomodulator and dual inhibitor of CCR2 and CCR5 being evaluated for the treatment of nonalcoholic steatohepatitis (NASH) and HIV. A Phase 2 trial currently underway is studying CVC in patients with NASH. Tobira also plans to advance CVC in a fixed-dose combination for HIV type 1 infection through Phase 3 development and commercialization in collaboration with a strategic partner or with non-dilutive financing. Learn more at www.tobiratherapeutics.com.

Certain statements contained in this news release, other than statements of fact that are independently verifiable at the date hereof, may constitute forward-looking information and forward-looking statements (collectively “forward-looking statements” within the meaning of applicable securities laws). Such statements, based as they are on the current expectations of management of Tobira Therapeutics and upon what management believes to be reasonable assumptions based on information currently available to it, inherently involve numerous risks and uncertainties, known and unknown, many of which are beyond Tobira’s control. Such statements can usually be identified by the use of words such as “may,” “would,” “believe,” “intend,” “plan,” “anticipate,” “estimate” and other similar terminology, or state that certain actions, events or results “may” or “would” be taken, occur or be achieved.

Whether actual results and developments will conform with our expectations and predictions is subject to a number of risks, assumptions and uncertainties, many of which are beyond our control, and the effects of which can be difficult to predict. These risks include those inherent in drug development, whether Tobira will be able to obtain financing when needed or on favorable terms, and other risks described in Tobira’s filings with the Securities and Exchange Commission. In evaluating any forward-looking statements in this release, Tobira cautions readers not to place undue reliance on any forward-looking statements. Unless otherwise required by applicable securities laws, Tobira does not intend, nor does it undertake any obligation, to update or revise any forward-looking statements contained in this news release to reflect subsequent information, events, results or circumstances or otherwise.


Chris PeetzChief Financial OfficerTobira Therapeutics(650) 351-5018cpeetz@tobiratherapeutics.com

Mark CorbaeCanale Communications(619) 849-5375mark@canalecomm.com 
SOURCE Tobira Therapeutics, Inc.